145 related articles for article (PubMed ID: 28445715)
1. Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Alam M; Rumpel R; Jin X; von Wrangel C; Tschirner SK; Krauss JK; Grothe C; Ratzka A; Schwabe K
Exp Neurol; 2017 Aug; 294():19-31. PubMed ID: 28445715
[TBL] [Abstract][Full Text] [Related]
2. Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
Jin X; Schwabe K; Krauss JK; Alam M
Exp Brain Res; 2016 Apr; 234(4):1105-18. PubMed ID: 26724931
[TBL] [Abstract][Full Text] [Related]
3. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
[TBL] [Abstract][Full Text] [Related]
4. Effect of deep brain stimulation on levodopa-induced dyskinesias and striatal oscillatory local field potentials in a rat model of Parkinson's disease.
Alam M; Capelle HH; Schwabe K; Krauss JK
Brain Stimul; 2014; 7(1):13-20. PubMed ID: 24126192
[TBL] [Abstract][Full Text] [Related]
5. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Miguelez C; Morera-Herreras T; Ugedo L
Neurobiol Dis; 2016 May; 89():88-100. PubMed ID: 26852950
[TBL] [Abstract][Full Text] [Related]
6. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
8. Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Tohge R; Kaneko S; Morise S; Oki M; Takenouchi N; Murakami A; Nakamura M; Kusaka H; Yakushiji Y
Neuropharmacology; 2021 Oct; 198():108771. PubMed ID: 34474045
[TBL] [Abstract][Full Text] [Related]
9. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
11. Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Van Kampen JM; Stoessl AJ
Neuroscience; 2000; 98(1):61-7. PubMed ID: 10858612
[TBL] [Abstract][Full Text] [Related]
12. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
13. Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Funamizu Y; Nishijima H; Ueno T; Ueno S; Mizukami H; Yagihashi S; Tomiyama M
Neurosci Res; 2017 Aug; 121():49-53. PubMed ID: 28392304
[TBL] [Abstract][Full Text] [Related]
14. Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Figge DA; Eskow Jaunarajs KL; Standaert DG
J Neurosci; 2016 Jun; 36(24):6514-24. PubMed ID: 27307239
[TBL] [Abstract][Full Text] [Related]
15. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
16. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Bibbiani F; Oh JD; Petzer JP; Castagnoli N; Chen JF; Schwarzschild MA; Chase TN
Exp Neurol; 2003 Nov; 184(1):285-94. PubMed ID: 14637099
[TBL] [Abstract][Full Text] [Related]
17. The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Iyer V; Venkiteswaran K; Savaliya S; Lieu CA; Handly E; Gilmour TP; Kunselman AR; Subramanian T
Neurobiol Dis; 2021 Nov; 159():105491. PubMed ID: 34461264
[TBL] [Abstract][Full Text] [Related]
18. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
[TBL] [Abstract][Full Text] [Related]
19. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Paillé V; Brachet P; Damier P
Neuroreport; 2004 Mar; 15(3):561-4. PubMed ID: 15094523
[TBL] [Abstract][Full Text] [Related]
20. Altered inhibitory interaction among inferior frontal and motor cortex in l-dopa-induced dyskinesias.
Ponzo V; Picazio S; Benussi A; Di Lorenzo F; Brusa L; Caltagirone C; Koch G
Mov Disord; 2016 May; 31(5):755-9. PubMed ID: 26861941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
